Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.0K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.0K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

4.7K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.7K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.2K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.2K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

778
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
778

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring prevalence and drivers of perimenopause uncertainty among US Women: a mixed-methods study.

Menopause (New York, N.Y.)·2026
Same author

Sexual Satisfaction and Orgasm Experiences During Partnered and Solo Sex Among 27,931 Users of the Flo App.

Archives of sexual behavior·2026
Same author

The past and future of integrated biopsychosocial whole-health perspectives in psychiatric rehabilitation.

Psychiatric rehabilitation journal·2026
Same author

Sexuality and sexual health in older adults-recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).

Sexual medicine reviews·2025
Same author

Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes: A Randomized Clinical Trial.

JAMA network open·2025
Same author

Sexual Desire and Fantasy Differ for Plurisexual vs Monosexual People in Mixed-Gender Relationships.

Journal of sex & marital therapy·2025

Related Experiment Video

Updated: Mar 15, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

685

Antidepressant-Induced Female Sexual Dysfunction.

Tierney Lorenz1, Jordan Rullo2, Stephanie Faubion3

  • 1Kinsey Institute and Center for the Integrative Study of Animal Behavior, Indiana University, Bloomington; Dr Lorenz is now with the Department of Psychology, University of North Carolina at Charlotte.

Mayo Clinic Proceedings
|September 6, 2016
PubMed
Summary

Antidepressant use can cause female sexual dysfunction. Clinicians must assess and manage these side effects through medication adjustments, behavioral changes, or complementary therapies for improved patient outcomes.

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.2K
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

40.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

685
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.2K
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

40.3K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Sexual Health

Background:

  • 1 in 6 women in the U.S. use antidepressants.
  • Antidepressants can cause sexual dysfunction in a substantial proportion of patients.
  • Differentiating antidepressant-related sexual dysfunction from underlying mood disorder symptoms is crucial.

Purpose of the Study:

  • To outline assessment and management strategies for antidepressant-related female sexual dysfunction.
  • To provide clinicians with guidance on addressing common adverse sexual effects of antidepressants.

Main Methods:

  • Review of current literature on antidepressant-related sexual dysfunction.
  • Discussion of diagnostic challenges and differential etiologies.
  • Categorization of management strategies including pharmacological, behavioral, and complementary approaches.

Main Results:

  • Careful assessment of sexual function before and during antidepressant treatment is critical.
  • Management options include dose modification, switching medications, augmentation, behavioral interventions, and complementary therapies.
  • A combination of approaches may be most effective for managing complex cases.

Conclusions:

  • Antidepressant-related female sexual dysfunction is a common and manageable condition.
  • A systematic approach to assessment and treatment is essential for patient care.
  • Clinicians need to be proficient in identifying and treating these adverse effects.